The Drug Enforcement Administration will host public listening sessions Sept. 12-13 to receive additional input on whether to permit telemedicine prescribing for certain controlled substances without any in-person medical evaluation, and data or other safeguards to prevent and detect their diversion. Registration for in-person attendance and for organizations wishing to make oral presentations opens Monday. Oral presentations may be 
given in-person or by video teleconference. Registrations are due Aug. 21. DEA will also livestream the listening sessions online.

The DEA and the Substance Abuse and Mental Health Services Administration in May released a temporary rule extending telehealth prescribing flexibilities for buprenorphine and other controlled substances through Nov. 11, 2024, while they develop final regulations, as urged by the AHA. Among other changes, AHA has urged the DEA to establish a special registration process (as statutorily mandated) to waive the in-person evaluations for practitioners who register with the agency.

Related News Articles

Headline
The AHA June 14 sent a letter to the Senate Finance Committee, responding to questions included in a white paper the committee wrote on chronic care through…
Headline
The Centers for Disease Control and Prevention June 13 issued a Health Alert Network Health Advisory following a federal health care fraud indictment against…
Headline
The House Energy and Commerce Committee June 12 passed AHA-supported legislation during a markup of bills that passed the Health Subcommittee in May. The…
Headline
Chris DeRienzo, M.D., AHA senior vice president and chief physician executive, speaks with three experts about how the award-winning Women and Infant Substance…
Headline
The House Energy and Commerce Subcommittee on Health May 16 passed a number of bills during a markup session, including AHA-supported legislation. The…
Headline
AHA submitted a statement May 8 to the House Ways and Means Committee for a markup session on proposed legislation impacting telehealth access for patients and…